EFFECT OF ADDING ALENDRONATE TO HORMONE REPLACEMENT THERAPY ON BONE MINERAL DENSITY IN ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS

Year 2000, Volume: 13 Issue: 4, 196 - 200, 03.12.2016

Mithat Erenus Ayşegül Gürler Sedef Binöz

Abstract

Objective: The purpose of this prospective randomized study was to evaluate the impact of adding alendronate to hormone replacement therapy (HRT) in established postmenopausal osteoporosis.
Patients: Forty patients were randomly assigned to receive either 0,625 mg. conjugated estrogen with 2,5 mg. medroxyprogesterone acetate (HRT) alone or HRT combined with 10 mg. alendronate daily for one year. Both groups received a daily supplement of 500 mg. of elemental calcium. Bone mineral density of lumbar spine and femur neck were measured prior to treatment and at the end of one year by dual energy X-ray absorptiometry.
Results: Nineteen patients from alendronate and HRT group, 18 patients from HRT group completed the study. HRT group had an increase in bone mineral density of 7,5±0,02% at lumbar spine (p<0.01) and 11,6±0,04% at femur neck (p<0,001). Whereas alendronate and HRT group had a mean increase in bone mineral density of 7,8±0,02% at lumbar spine (p<0.01) and 17,8±0,02% at femur neck (p<0.01). Both treatments were well tolerated.
Conclusions: Both HRT alone and HRT combined with alendronate treatments in postmenopausal osteoporosis appears to
increase bone mineral density at spine and femur neck. There is a greater increase in bone mineral density at femur with HRT alendronate combination treatment which did not achieve significance.
Key Words: Alendronate, Hormone
replacement therapy, Bone density

References

• /. Riggs BL, Melton 1J III. Tile prevention and treatment of osteoporosis. M Engl J Med 1992;327:620-627.
• Watts MB. Postmenopausal osteoporosis. Obstet Gynecol Surv 1999:54:532-538.
• Speroff L, Glass Rfl, Rase TIG. Clinical Gynecologic Endocrinology and Infertility. In: Postmenopausal hormone therapy, 6th ed. Philadelphia: Lippincott Williams Sr Wilkins, 1999:725-729.
• Grady D, Rubin SM, Petitti DB. Mormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;! 17:1016-1037.
• Speroff L, Rowan J, Symons W, et ai. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA 1996;276:1397-1403.
• The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEP!) trial. JAMA 1996:276:1389-1396.
• Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. H Engl J Med 1995:333:1437- 1443.
• Mosking D, Chilvers C, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. M Engl J Med 1998:338:485-491.
• McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 1998;128:253-261.
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1993:280:2077- 2082.
• I I. Ensrud RE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women highest risk. Arch Intern Med 1997;157:2617-2624.
• Eiken P, Rolthoff M, Mielscn SP. Effect of 10 years hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 19:191 s.
• Stock JL, Bell MM, Chestnut CH, et al. Increments in bone mineral density of the
• lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-297.
• Devogelaer JP, Broil ft, Correa- Rotter R, et ai. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal
• women with osteoporosis. Bone 1996;18:141-150.
• TucciJR, Tonino RF, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101 -.488-501.
• Lindsay R, Mart DM, Mac Lean A, et al. Bone response to termination of estrogen treatment. Lancet 1978; 1:1325-1327.